The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Birken AG, a biopharmaceutical and dermo-cosmetic company has announced that the European Medicines Agency (EMA) has accepted its Oleogel-S10 Marketing...
Drivers for disease and meeting the challenge of wound healing
Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
The European Commission has approved Filsuvez (Oleogel-S10) from Amryt for the treatment of skin wounds in adults and children, ages 6 months and older, with dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB).
Amryt announces that the British Journal of Dermatology has published full results from the double-blind phase of its pivotal Phase III trial, EASE
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that the FDA approved Filsuvez (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB)
EB in clinical practice and implications for change
Symposium overview and meet the experts
A new era for epidermolysis bullosa